1. Male or female subjects of =18 to 60 years of age. 2. Subjects willing to give informed consent and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures 3. Confirmed case of COVID-19 infection by RT-PCR and mild and moderate (without oxygen therapy or assisted ventilation) cases of COVID-19. Scores of 2-4 on the WHO Clinical Progression Scale 4. Time interval between symptoms onset and randomization of no more than 7 days 5. One or more of the following symptoms: ? Fever ? Cough ? Sore throat ? Headache Nasal congestion ? Malaise ? Diarrhea ? Loss of smell ? Loss of taste 6. Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 30 days after the last dose of assigned treatment. A subject is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.

1. Male or female subjects of =18 to 60 years of age. 2. Subjects willing to give informed consent and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures 3. Confirmed case of COVID-19 infection by RT-PCR and mild and moderate (without oxygen therapy or assisted ventilation) cases of COVID-19. Scores of 2-4 on the WHO Clinical Progression Scale 4. Time interval between symptoms onset and randomization of no more than 7 days 5. One or more of the following symptoms: ? Fever ? Cough ? Sore throat ? Headache Nasal congestion ? Malaise ? Diarrhea ? Loss of smell ? Loss of taste 6. Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 30 days after the last dose of assigned treatment. A subject is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.